X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (734) 734
male (551) 551
rats (535) 535
taurocholic acid - pharmacology (297) 297
index medicus (213) 213
taurocholic acid (200) 200
humans (191) 191
taurocholic acid - administration & dosage (178) 178
female (153) 153
taurocholic acid - metabolism (144) 144
rats, sprague-dawley (143) 143
rats, wistar (140) 140
liver - metabolism (139) 139
pharmacology & pharmacy (134) 134
bile acids and salts - metabolism (129) 129
gastroenterology & hepatology (129) 129
pancreatitis - chemically induced (124) 124
rats, inbred strains (116) 116
acute disease (111) 111
bile - metabolism (104) 104
mice (104) 104
disease models, animal (103) 103
time factors (87) 87
dogs (81) 81
liver - drug effects (81) 81
pancreas - pathology (76) 76
pancreatitis (76) 76
pancreatitis - pathology (73) 73
liver (72) 72
gastric mucosa - drug effects (71) 71
rat (69) 69
bile acids (65) 65
taurocholic acid - analogs & derivatives (64) 64
acute pancreatitis (63) 63
bile (63) 63
amylases - blood (59) 59
inflammation (58) 58
research article (57) 57
hydrogen-ion concentration (56) 56
administration, oral (55) 55
dose-response relationship, drug (55) 55
physiology (53) 53
taurocholate (52) 52
kinetics (50) 50
taurocholic acid - toxicity (50) 50
adult (49) 49
pancreatitis - metabolism (49) 49
bile acids and salts - pharmacology (48) 48
expression (48) 48
pancreas - drug effects (48) 48
pancreatitis - drug therapy (48) 48
absorption (46) 46
permeability (46) 46
bile - secretion (45) 45
taurocholic acid - chemistry (45) 45
rodents (44) 44
gastric mucosa - metabolism (43) 43
intestinal absorption (43) 43
pancreas - metabolism (43) 43
bile - drug effects (42) 42
perfusion (41) 41
surgery (41) 41
injections, intravenous (40) 40
cholesterol - metabolism (39) 39
pancreatitis, acute necrotizing - chemically induced (39) 39
secretion (39) 39
taurocholic acid - pharmacokinetics (39) 39
biochemistry & molecular biology (38) 38
biological transport (38) 38
endocrinology & metabolism (37) 37
in vitro techniques (37) 37
intestinal absorption - drug effects (37) 37
middle aged (37) 37
metabolism (36) 36
model (36) 36
necrosis (36) 36
acids (35) 35
cytokines (35) 35
transport (35) 35
gastroenterology and hepatology (34) 34
activation (33) 33
medicine, research & experimental (33) 33
pancreas (33) 33
cholagogues and choleretics - pharmacology (32) 32
medicine (32) 32
analysis (31) 31
injury (31) 31
inhibition (30) 30
lung injury (30) 30
biological transport - drug effects (29) 29
cells (29) 29
cholesterol (29) 29
deoxycholic acid (29) 29
proteins (29) 29
taurocholic acid - adverse effects (29) 29
mice, inbred c57bl (28) 28
oncology (28) 28
physiological aspects (28) 28
bile acids and salts - secretion (27) 27
diet (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (841) 841
German (5) 5
Chinese (3) 3
Japanese (3) 3
Polish (3) 3
Spanish (3) 3
French (2) 2
Italian (2) 2
Hungarian (1) 1
Russian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 06/2012, Volume 81, Issue 2, pp. 265 - 272
Journal Article
Gut, ISSN 0017-5749, 09/2003, Volume 52, Issue 9, pp. 1371 - 1375
Background: Whether ileal absorption of bile acid is up or downregulated in chronic cholestasis is still debated, and most evidence has come from animal... 
Studies | Liver diseases | Acids | Rodents | Gallbladder diseases | Retention | Patients | Bile
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 03/2014, Volume 177, Issue 1, pp. 64 - 73
Journal Article
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 09/2014, Volume 189, pp. 80 - 89
Here, we report reduced graphene oxide (rGO) nanosheets coated with an anti-angiogenic anticancer taurocholate derivative of low-molecular-weight heparin... 
Anticancer effect | Reduced graphene oxide | Doxorubicin | Anti-angiogenic anticancer low molecular weight heparin derivative | Dispersion stability | DISPERSIONS | VIVO | CHEMISTRY, MULTIDISCIPLINARY | FUNCTIONALIZATION | IN-VITRO | CO-DELIVERY | THERAPY | TAUROCHOLATE CONJUGATE | PHARMACOLOGY & PHARMACY | BIOMEDICAL APPLICATIONS | Heparin, Low-Molecular-Weight - analogs & derivatives | Humans | Drug Carriers - administration & dosage | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Graphite - administration & dosage | Female | Taurocholic Acid - chemistry | Graphite - chemistry | Taurocholic Acid - analogs & derivatives | Doxorubicin - administration & dosage | Cell Survival - drug effects | Oxidation-Reduction | Drug Stability | Heparin, Low-Molecular-Weight - chemistry | Antineoplastic Agents - chemistry | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Taurocholic Acid - administration & dosage | Adsorption | Tumor Burden - drug effects | Mice, Nude | Nanostructures - administration & dosage | Cell Line, Tumor | Nanostructures - chemistry | Mice, Inbred BALB C | Heparin, Low-Molecular-Weight - administration & dosage | Neoplasms - pathology | Antimitotic agents | Glycosaminoglycans | Graphene | Fluorescein | Graphite | Anticoagulants (Medicine) | Antineoplastic agents | Anthracyclines | Pharmacy | Fluorescence | Tumors | Index Medicus
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 168 - 176
This study investigated the role of a multispecific organic anion transporter, Oatp1a4/ Slco1a4 , in drug transport across the blood-brain barrier. In vitro... 
LOCALIZATION | INVOLVEMENT | POLYPEPTIDE-2 | PENETRATION | PHARMACOLOGY & PHARMACY | RAT-BRAIN | OATP2 | BCRP/ABCG2 | 17-BETA-ESTRADIOL-D-17-BETA-GLUCURONIDE | CANCER RESISTANCE PROTEIN | P-GLYCOPROTEIN | Fluorobenzenes - pharmacokinetics | Gene Expression - genetics | Pyrimidines - blood | Humans | Ion Pumps - genetics | Fluorobenzenes - administration & dosage | Quinolines - administration & dosage | Pyrimidines - metabolism | Brain - metabolism | Quinolines - pharmacokinetics | Choroid Plexus - blood supply | ATP-Binding Cassette Transporters - genetics | Ochratoxins - administration & dosage | Cell Membrane - metabolism | Cerebral Cortex - drug effects | Capillaries - metabolism | Fluorobenzenes - metabolism | Tetrahydroisoquinolines - pharmacology | Organic Cation Transport Proteins - metabolism | Pravastatin - metabolism | Liver - metabolism | Rosuvastatin Calcium | Sulfonamides - pharmacokinetics | Blood-Brain Barrier - metabolism | Mice, Knockout | Brain - drug effects | Taurocholic Acid - administration & dosage | Pravastatin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - administration & dosage | Pyrimidines - pharmacokinetics | Mice | Kinetics | Organic Cation Transport Proteins - genetics | Pravastatin - pharmacokinetics | Sulfonamides - administration & dosage | Quinolines - blood | Digoxin - metabolism | Taurocholic Acid - metabolism | Choroid Plexus - metabolism | Taurocholic Acid - blood | Ochratoxins - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Ochratoxins - metabolism | Cerebral Cortex - metabolism | Organic Anion Transporters - metabolism | Brain - blood supply | Sulfonamides - blood | Organic Anion Transporters - genetics | Transfection | Fluorobenzenes - blood | Enkephalin, D-Penicillamine (2,5)- - pharmacokinetics | Recombinant Proteins - metabolism | Cell Line | Pyrimidines - administration & dosage | Mice, Inbred C57BL | Recombinant Proteins - genetics | Blood-Brain Barrier - drug effects | Digoxin - pharmacokinetics | Quinolines - metabolism | Taurocholic Acid - pharmacokinetics | Liver - blood supply | Pharmaceutical Preparations - metabolism | Animals | Digoxin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - metabolism | Acridines - pharmacology | Sulfonamides - metabolism
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 7/2015, Volume 32, Issue 7, pp. 2318 - 2327
To overcome definite limitations of angiogenesis inhibitors such as insufficient therapeutic efficacy as a single drug and resisting or conflicting effect... 
Biochemistry, general | Biomedical Engineering | hypoxia | Biomedicine | Pharmacy | angiogenesis | cyclooxygenase-2 | Medical Law | combination therapy | heparin conjugate | Pharmacology/Toxicology | Angiogenesis | Hypoxia | Cyclooxygenase-2 | Combination therapy | Heparin conjugate | PATHWAYS | METASTASIS | MACROPHAGES | TUMOR ANGIOGENESIS | CELECOXIB | CHEMISTRY, MULTIDISCIPLINARY | CELL CARCINOMA | ANTIANGIOGENIC THERAPY | INFLAMMATION | PHARMACOLOGY & PHARMACY | CANCER PREVENTION | Human Umbilical Vein Endothelial Cells | Celecoxib - administration & dosage | Heparin, Low-Molecular-Weight - pharmacology | Heparin, Low-Molecular-Weight - analogs & derivatives | Humans | Male | Celecoxib - chemistry | Heparin, Low-Molecular-Weight - therapeutic use | Neovascularization, Pathologic - pathology | Cyclooxygenase 2 - biosynthesis | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Cyclooxygenase 2 Inhibitors - therapeutic use | Angiogenesis Inhibitors - therapeutic use | Taurocholic Acid - chemistry | Drug Therapy, Combination | Taurocholic Acid - analogs & derivatives | Taurocholic Acid - pharmacology | Cell Hypoxia - drug effects | Cyclooxygenase 2 Inhibitors - pharmacology | Cyclooxygenase 2 Inhibitors - administration & dosage | Angiogenesis Inhibitors - pharmacology | Heparin, Low-Molecular-Weight - chemistry | Celecoxib - pharmacology | Celecoxib - therapeutic use | Mice, Inbred Strains | Xenograft Model Antitumor Assays | Animals | Taurocholic Acid - administration & dosage | Neovascularization, Pathologic - drug therapy | Taurocholic Acid - therapeutic use | Neovascularization, Pathologic - metabolism | Heparin, Low-Molecular-Weight - administration & dosage | Angiogenesis Inhibitors - chemistry | Drugstores | COX-2 inhibitors | Neovascularization | Angiogenesis inhibitors | Deoxycholic acid | Inhibitor drugs | Pharmaceutical sciences | Tumors
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 03/2016, Volume 501, Issue 1-2, pp. 1 - 9
Nanoparticulate drug delivery systems, mucoadhesive polymers and penetration enhancers have been used individually to overcome ocular barriers and increase... 
Nanoparticles | Capric acid | Pluronic F68 | Non-invasive | Sodium taurocholate | Penetration enhancer | Benzalkonium chloride | EDTA | Ocular drug delivery | Sodium glycocholate | PERMEATION ENHANCERS | DRUG-DELIVERY | CHITOSAN NANOPARTICLES | POLYCAPROLACTONE | MICROPARTICLES | GLUTARALDEHYDE | CORNEAL | TRANSPORT | PHARMACOLOGY & PHARMACY | ABSORPTION PROMOTERS | PLGA NANOPARTICLES | Nanoparticles - chemistry | Biological Availability | Coumarins - chemistry | Glycolates - chemistry | Drug Delivery Systems | Surface Properties | Decanoic Acids - chemistry | Eye - drug effects | Taurocholic Acid - chemistry | Glutaral - chemistry | Gelatin - chemistry | Eye - metabolism | Cell Line | Cell Survival - drug effects | Rabbits | Glycolates - administration & dosage | Microscopy, Electron, Scanning | Permeability - drug effects | Nanoparticles - ultrastructure | Benzalkonium Compounds - administration & dosage | Benzalkonium Compounds - chemistry | Decanoic Acids - administration & dosage | Mucins - chemistry | Edetic Acid - administration & dosage | Animals | Edetic Acid - chemistry | Taurocholic Acid - administration & dosage | Polymers - chemistry | Thiazoles - chemistry | Mice | Nanoparticles - administration & dosage | Drugs | Drug delivery systems | Surface active agents | Ophthalmic drugs | Permeability | Saturated fatty acids | Vehicles
Journal Article
American Journal of Physiology - Gastrointestinal and Liver Physiology, ISSN 0193-1857, 03/2007, Volume 292, Issue 3, pp. G718 - G724
Salivary nitrate from dietary or endogenous sources is reduced to nitrite by oral bacteria. In the acidic stomach, nitrite is further reduced to bioactive... 
Rats | Laser-Doppler flowmetry | Endothelial nitric oxide synthase deficient | chromium-labeled EDTA clearance | Gastric mucus | Nitrite | PHYSIOLOGY | INTRAGASTRIC NITRIC-OXIDE | ACID | RAT | PERMEABILITY | PROTECTION | BICARBONATE | laser-Doppler flowmetry | endothelial nitric oxide synthase deficient | gastric mucus | nitrite | IN-VIVO | LASER-DOPPLER | rats | GASTROENTEROLOGY & HEPATOLOGY | STOMACH | THICKNESS | Diclofenac - pharmacology | Nitrates - pharmacology | Nitrites - metabolism | Male | Mucus - drug effects | Stomach - metabolism | Nitrites - administration & dosage | Vascular Resistance - physiology | Regional Blood Flow - drug effects | Gastric Mucosa - drug effects | Vascular Resistance - drug effects | Mucus - metabolism | Blood Pressure - drug effects | Stomach - drug effects | Gastric Mucosa - blood supply | Taurocholic Acid - pharmacology | Permeability - drug effects | Administration, Oral | Mice, Inbred C57BL | Nitric Oxide Synthase Type III | Nitrites - pharmacology | Rats, Sprague-Dawley | Nitrates - administration & dosage | Mice, Knockout | Animals | Taurocholic Acid - administration & dosage | Nitric Oxide Synthase Type II - genetics | Gastric Mucosa - physiology | Mice | Mucus - chemistry | Diclofenac - administration & dosage | Nitric Oxide - metabolism | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICINE | Nitric Oxide/metabolism | Mice; Inbred C57BL | Nitric Oxide Synthase Type II/genetics | Gastric Mucosa/blood supply/drug effects/physiology | Diclofenac/administration & dosage/pharmacology | Regional Blood Flow/drug effects | Rats; Sprague-Dawley | Administration; Oral | Taurocholic Acid/administration & dosage/pharmacology | Mice; Knockout | Mucus/chemistry/drug effects/metabolism | Nitrites/administration & dosage/metabolism/pharmacology | Permeability/drug effects | Blood Pressure/drug effects | MEDICIN | Stomach/drug effects/metabolism | Vascular Resistance/drug effects/physiology | Nitrates/administration & dosage/pharmacology
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 01/2015, Volume 197, pp. 180 - 189
Angiogenesis is a key feature of cancer development, thus it is a good target for cancer therapy. However, drugs that have been designed to block angiogenesis... 
Anti-angiogenesis | Heparin conjugate | Protamine | Self-assembled nanocomplex | SYSTEM | CHITOSAN | POLYELECTROLYTE COMPLEXES | CHEMISTRY, MULTIDISCIPLINARY | DELIVERY | HETEROGENEITY | BIOMARKERS | NANOPARTICLES | SULFATE | PHARMACOLOGY & PHARMACY | TUMOR MICROENVIRONMENT | Heparin, Low-Molecular-Weight - analogs & derivatives | Protamines - toxicity | Humans | Male | Polyethylene Glycols - chemistry | Neovascularization, Pathologic - pathology | Angiogenesis Inhibitors - administration & dosage | Protamines - administration & dosage | Taurocholic Acid - chemistry | Taurocholic Acid - analogs & derivatives | Protamines - chemistry | Heparin, Low-Molecular-Weight - toxicity | Heparin, Low-Molecular-Weight - chemistry | Angiogenesis Inhibitors - pharmacokinetics | Taurocholic Acid - toxicity | Rats, Sprague-Dawley | Mice, Inbred C3H | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Taurocholic Acid - pharmacokinetics | Heparin, Low-Molecular-Weight - pharmacokinetics | Animals | Taurocholic Acid - administration & dosage | Angiogenesis Inhibitors - toxicity | Tumor Burden - drug effects | Mice, Nude | Nanostructures - administration & dosage | Neovascularization, Pathologic - drug therapy | Protamines - pharmacokinetics | Cell Line, Tumor | Nanostructures - chemistry | Heparin, Low-Molecular-Weight - administration & dosage | Nanostructures - toxicity | Neoplasms - pathology | Angiogenesis Inhibitors - chemistry | Drugs | Drug delivery systems | Glycosaminoglycans | Polyelectrolytes | Anticoagulants (Medicine) | Polyols | Vehicles | Polyethylene glycol | Collagen | Biomedical engineering | Pharmaceutical biotechnology
Journal Article